Leland Gershell
Stock Analyst at Oppenheimer
(2.15)
# 265
Out of 4,667 analysts
128
Total ratings
41.05%
Success rate
-6.7%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Outperform | $190 → $180 | $124.38 | +44.72% | 10 | Nov 15, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $48 → $52 | $20.77 | +150.36% | 2 | Nov 11, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $135 → $147 | $111.56 | +31.77% | 2 | Nov 8, 2024 | |
| VERU Veru Inc. | Reiterates: Outperform | $5 | $0.63 | +699.62% | 8 | Nov 5, 2024 | |
| EPIX ESSA Pharma | Downgrades: Perform | n/a | $1.73 | - | 2 | Nov 4, 2024 | |
| ARGX argenx SE | Reiterates: Outperform | $560 → $646 | $591.82 | +9.15% | 4 | Nov 1, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $65 → $73 | $54.83 | +33.14% | 8 | Oct 28, 2024 | |
| URGN UroGen Pharma | Reiterates: Outperform | $40 | $11.45 | +249.34% | 9 | Oct 16, 2024 | |
| IMVT Immunovant | Maintains: Outperform | $47 → $53 | $26.17 | +102.52% | 3 | Oct 9, 2024 | |
| BBIO BridgeBio Pharma | Initiates: Perform | n/a | $23.04 | - | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $43 | $18.92 | +127.27% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $7.50 | +300.00% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.06 | +292.16% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $1.28 | +1,853.13% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $19.79 | +41.49% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $2.31 | +982.25% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $56.07 | +30.19% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $4.32 | +200.93% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $3.45 | +479.71% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $21.15 | +37.12% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $10.90 | +221.10% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $1.09 | +817.43% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $3.06 | +63.40% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $2.77 | +224.91% | 2 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $2.03 | +887.65% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $248.79 | - | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.86 | +598.92% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $0.34 | +1,075.09% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $62.56 | - | 2 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.09 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7,200 | $0.51 | +1,410,558.31% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $17.03 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $5.26 | +850.57% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4,620 → $1,470 | $3.71 | +39,522.64% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $0.49 | - | 5 | Mar 31, 2020 |
Ascendis Pharma
Nov 15, 2024
Maintains: Outperform
Price Target: $190 → $180
Current: $124.38
Upside: +44.72%
Dianthus Therapeutics
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $20.77
Upside: +150.36%
Ligand Pharmaceuticals
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $111.56
Upside: +31.77%
Veru Inc.
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.63
Upside: +699.62%
ESSA Pharma
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.73
Upside: -
argenx SE
Nov 1, 2024
Reiterates: Outperform
Price Target: $560 → $646
Current: $591.82
Upside: +9.15%
Soleno Therapeutics
Oct 28, 2024
Maintains: Outperform
Price Target: $65 → $73
Current: $54.83
Upside: +33.14%
UroGen Pharma
Oct 16, 2024
Reiterates: Outperform
Price Target: $40
Current: $11.45
Upside: +249.34%
Immunovant
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $26.17
Upside: +102.52%
BridgeBio Pharma
Oct 3, 2024
Initiates: Perform
Price Target: n/a
Current: $23.04
Upside: -
Sep 25, 2024
Maintains: Outperform
Price Target: $15 → $43
Current: $18.92
Upside: +127.27%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $7.50
Upside: +300.00%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.06
Upside: +292.16%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $1.28
Upside: +1,853.13%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $19.79
Upside: +41.49%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $2.31
Upside: +982.25%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $56.07
Upside: +30.19%
Aug 2, 2024
Maintains: Outperform
Price Target: $16 → $13
Current: $4.32
Upside: +200.93%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $3.45
Upside: +479.71%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $21.15
Upside: +37.12%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $10.90
Upside: +221.10%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $1.09
Upside: +817.43%
Mar 28, 2024
Initiates: Outperform
Price Target: $5
Current: $3.06
Upside: +63.40%
Mar 21, 2024
Maintains: Outperform
Price Target: $9
Current: $2.77
Upside: +224.91%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $2.03
Upside: +887.65%
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $248.79
Upside: -
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.86
Upside: +598.92%
Mar 24, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $0.34
Upside: +1,075.09%
Feb 22, 2023
Downgrades: Perform
Price Target: n/a
Current: $62.56
Upside: -
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.09
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $7,200
Current: $0.51
Upside: +1,410,558.31%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $17.03
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $5.26
Upside: +850.57%
Sep 25, 2020
Maintains: Outperform
Price Target: $4,620 → $1,470
Current: $3.71
Upside: +39,522.64%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $0.49
Upside: -